We have elucidated the genetic defect in a 66-yr-old patient with fish eye syndrome (FES) presenting with severe corneal opacities and hypoalphalipoproteinemia. The patient's plasma concentration of high density lipoprotein (HDL) cholesterol was reduced at 7.7 mg/dl (35.1-65.3 mg/dl in controls) and the HDL cholesteryl ester content was 31% (60-80% in controls); however, total plasma cholesteryl esters were similar to normal (60% of total cholesterol vs. a mean of 66% in controls). The patient's plasma cholesterol esterification rate was slightly reduced at 51 nmol/ml per h (control subjects: 61-106 nmol/ml per h), whereas lecithin-cholesterol acyltransferase (LCAT) activity, assayed using a HDL-like exogenous proteoliposome substrate, was virtually absent (0.9 nmol/ml per h vs. 25.1-27.9 nmol/ml per h in control subjects). DNA sequence analysis of the proband's LCAT gene revealed two separate C to T transitions resulting in the substitution of Thr23 with Ile and Thr347 with Met. The mutation at codon 347 created a new restriction site for the enzyme Nla III. Analysis of the patient's polymerase chain reaction-amplified DNA containing the region of the Thr347 mutation by digestion with Nla III confirmed that the proband is a compound heterozygote for both defects. The patient's daughter, who is asymptomatic despite a 50% reduction of LCAT activity, is heterozygous for the Thr, Ile mutation. Our data indicate that the regions adjacent to Thr123 and Thr347 of LCAT may play an important role in HDL cholesterol esterification, suggesting that these regions may contain a portion of the LCAT binding domain(s) for HDL. (J.
Introduction
Fish eye disease, which was first described in 1979 as a rare genetic disorder of lipid metabolism inherited as a recessive trait, is characterized by severe corneal opacities and hypoal-subjects. LCAT, an enzyme synthesized by hepatocytes and secreted into the plasma, is responsible for the esterification of virtually all free cholesterol in plasma. Cholesteryl esters formed by LCAT are subsequently incorporated primarily into HDL particles and are transported in plasma associated with HDL or transferred to VLDL or LDL by the cholesteryl ester transfer protein (4) .
The most striking biochemical finding in the Swedish patients was a 90% reduction in plasma HDL cholesteryl ester concentration, but normal cholesterol esterification rates as well as normal levels of total plasma cholesteryl esters (1) (2) (3) . Cross-incubation studies using HDL-or VLDL-and LDL-depleted plasma demonstrated that plasma from these subjects lacked the ability to esterify HDL cholesterol, whereas the esterification of VLDL and LDL cholesterol was similar to normal (7) (8) (9) . In vitro incubation experiments with plasma from these patients gave no evidence for either the presence of a plasma inhibitor of the enzyme or for an impaired cholesteryl ester transfer activity (6, 10, 12) . Therefore, two separate LCAT activities were postulated and designated as a-LCAT and f-LCAT, assuming separate enzyme activities on apo Aand apo B-containing lipoprotein particles, respectively (8- 1 1) . The three Swedish subjects were proposed to have a selective deficiency in a-LCAT activity and their disorder was termed fish eye disease. This condition differs from classic LCAT deficiency in which patients have a total loss of LCAT activity and a virtual absence of cholesterol esterification in plasma. Furthermore, the subjects with fish eye disease had no premature atherosclerosis, anemia or renal disease (4) (14) . The LCAT gene, which has been assumed to be genetically defective in fish eye disease, was analyzed in one of the Swedish patients by Southern blot hybridization, but no deletions, insertions or rearrangements were detected (15) . Recently, however, in four unrelated fish eye disease patients from one German and two Dutch kindreds, DNA sequence analysis identified a single point mutation in the LCAT gene, resulting in the substitution of threonine by isoleucine at position 123 (16, 17) . This defect has been proposed to be one of the underlying molecular defects leading to fish eye disease.
In this article we report the elucidation of the molecular defects of a German subject with fish eye disease and his healthy daughter. The proband is a compound heterozygote for the ThrI23 -) Ile mutation and a previously undescribed Thr347 --*Met mutation in the LCAT gene.
Methods
Proband. The healthy German patient, born in 1925, was referred for medical evaluation because of increasing corneal opacifications.
Blood samples. Fasting venous blood samples were collected in EDTA, and plasma forlipoprotein analysis was separated by centrifugation (1,500 g, 15 min) followed by storage at 4VC. Aliquots for LCAT assays were kept at -700.
Lipoprotein and apolipoprotein analysis. Lipoproteins were isolated by sequential ultracentrifugation as previously described (18) . The following density fractions were obtained: VLDL (d < 1.006 g/ml), IDL (1.006-1.019 g/ml), LDL (1.019-1.063 g/ml), HDL2 (1.063-1.121 g/ml), HDL3 (1.121-1.210 g/ml), and VHDL (1.210-1.250 g/ ml). Plasma triglycerides, total and free cholesterol were quantitated colorimetrically by the glycerolphosphate-oxidase peroxidase and cholesterol-oxidase peroxidase reactions, respectively, using commercial standardized test kits (Boehringer, Mannheim, Federal Republic of Germany). Phospholipids were assayed chromatographically as described (19) . Qualitative and quantitative lipoprotein electrophoresis was performed as reported elsewhere (20) . Apo A-I isoproteins were analyzed by two-dimensional gel electrophoresis (21) . Plasma levels of apo A-I were quantitated by nephelometry, using a standardized test kit (Boehringer). Apo A-Il was assayed by a specific ELISA as previously reported (22) .
Plasma cholesterol esterification rate (CER) and LCAT activity.
CER and LCAT activity were determined as previously reported (23) . The CER is defined as the rate ofesterification ofcholesterol contained within the endogenous lipoproteins ofplasma and is comparable to the total plasma LCAT activity. LCAT Restriction fragment length polymorphism analysis. Sequences surrounding the mutation identified in exon 6 of the human LCAT gene were amplified from genomic DNA ofthe proband, his daughter, and a control subject using the primer pair L (5'-GAAGGCTGG-TACCTGTGGCTGCAG-3') and M (5'-GCTGAAGACCAGGTT-GAGATGCTG-3'). PCR products were gel-purified and digested with 8 U of the polymorphic restriction enzyme Ma III for 4 h at 370C as outlined by the supplier (New England Biolabs, Beverly, MA). Restriction digests were separated on a 2% agarose (FMC BioProducts, Rockland, ME) minigel supplemented with 1% low melting point agarose at 30 mA for 3.5 h. DNA was stained with ethidium bromide.
Results
Lipoprotein and apolipoprotein analysis. Lipoprotein analyses ofthe proband and his daughter are summarized in Table I and compared with the data available from the Swedish patients and healthy control subjects (n = 120). The patient's plasma triglyceride and cholesterol levels were in the normal range, while HDL cholesterol was reduced to -14% of the mean control value. Both HDL subfractions, HDL2 and HDL3, were reduced in cholesterol to the same extent. 31% of the HDL cholesterol was esterified compared to a mean of 74% in normal subjects in this age group. LDL from the patient showed no abnormalities in content and proportional distribution of free and esterified cholesterol; however, triglycerides were increased by 50%. VLDL particles had normal levels of total cholesterol and triglycerides, but cholesterol esters in this subfraction tended to be slightly higher than in control individuals. Quanti Plasma CER and LCAT activity. Results of the LCAT assays are summarized in Table II . The CER in the proband was only slightly reduced, whereas LCAT activity measured by an HDL-like proteoliposome assay was < 5% of that present in healthy subjects. Analysis of CER in LDL-and VLDL-depleted plasma revealed that 34-41% ofthe activity was present on HDL particles in control subjects, whereas in the proband's plasma only 12% of CER was associated with HDL particles. The daughter had a 50% reduction in LCAT activity, but a normal CER in native as well as in VLDL-and LDL-depleted plasma.
DNA sequence analysis. The protein coding regions of the LCAT gene were sequenced in the patient and in a normal control using PCR-amplified DNA as a template (Fig. 2) . Sequence analysis of the LCAT gene from the proband revealed two point mutations: (a) a C to T substitution at nucleotide 13 of exon 4, resulting in the conversion of amino acid 123 of the mature protein, threonine (ACA), to isoleucine (ATA), and (b) a C to T substitution at nucleotide 364 of exon 6, replacing threonine (ACG) at position 347 with methionine (ATG). Analysis ofthese regions in the LCAT gene ofthe daughter demonstrated that she is heterozygous for the base substitution in exon 4, while the DNA sequence ofexon 6 was identical to the normal allele. heterozygous for this mutation. Digestion of PCR-amplified DNA from the daughter and from a control subject demonstrated the presence of only one uncleaved fragment (Fig. 3 (37) , LCAT deficiency (38) , fish eye disease (1), apo A-I, C-Ill deficiency (39) , apo C-III, A-I, A-IV deficiency (40) , fish eye-like dyslipoproteinemia (13) , and specific apo A-I variants (41, 42 Of particular interest are the patients characterized clinically by severe corneal opacifications and very low plasma HDL levels. The prominent corneal opacification led to the designation of fish eye disease in the original three Swedish patients with a-LCAT activity deficiency. The genetic defect in these subjects has not been reported. A young patient (born in 1969) from Canada has been described with a defect in a-LCAT activity similar to the Swedish patients; however, the patient clinically has only arcus. The molecular defect has not been ascertained, and this patient's condition has been designated as resembling fish eye disease (13) . Recently, four patients with severe corneal opacifications and absent a-LCAT activity comparable to the Swedish patients have been reported, and the molecular defect in these subjects was found to be a point mutation in the LCAT gene (16, 17) . In addition, another subject with severe corneal opacification, reduced a-LCAT activity and HDL deficiency has been identified. In this case the genetic defect was a frame shift mutation in the apo A-I gene (42). Thus, defects in both the LCAT and the apo A-I genes as well as the yet unknown defects in the Swedish and the Canadian patients result in the clinical features of severe corneal opacifications with HDL deficiency. Based on these results we propose to designate the condition ofpatients with the clinical features ofsevere corneal opacifications and HDL deficiency as fish eye syndrome to reflect the heterogeneity of the molecular defects now identified in patients previously designated as having fish eye disease.
DNA sequence analysis of the LCAT gene in our patient revealed the presence of a C to T point mutation in one allele, converting Thr123 to Ile as previously reported (16, 17) . This mutation was also detected in one allele ofthe proband's daughter. The patient's other allele was found to be affected by a second C to T point mutation, which replaced threonine at position 347 with methionine. DNA sequence analysis and digestion with the polymorphic restriction enzyme Ma III established that the patient is heterozygous for both nucleotide substitutions, whereas the daughter inherited only the Thr123 -O Ile mutation. The proband reported here therefore represents the first compound heterozygote for a defect in the LCAT gene resulting in fish eye syndrome, suggesting that the regions around amino acid 123 and residue 347 are both essential for normal LCAT activity.
The plasma lipid profile in our proband is consistent with those reported for the three Swedish patients and demonstrates the typical laboratory findings of hypoalphalipoproteinemia and decreased HDL cholesteryl ester concentrations. Normal levels of VLDL and LDL cholesteryl esters suggest a normal fl-LCAT activity on apo B-containing particles, which results in plasma concentrations of total cholesteryl esters in these patients similar to those of control subjects. A markedly increased triglyceride content was observed in the proband's LDL, but not in VLDL, although the increase in triglyceride content was not as high as that reported for the three Swedish patients. The loss of a-LCAT activity, demonstrated by the virtual absence ofesterification ofan exogenous HDL-like substrate or in VLDL-and LDL-depleted plasma, and the nearly normal cholesterol esterification rate in plasma are consistent with previous reports from the patients from Sweden. The proband's heterozygous daughter had a 50% reduction in a-LCAT activity, but no abnormalities in lipoprotein profile. This suggests that one normal LCAT allele is sufficient for HDL cholesterol esterification. This may also indicate that under normal conditions LCAT activity is not the rate-limiting step in the net rate of cholesterol esterification. Similarly, the decreased plasma enzyme levels reported in heterozygotes for classic LCAT deficiency were adequate to maintain a normal plasma esterification rate (43, 44) .
It may be speculated that both regions ofthe mature LCAT protein affected by the mutations reported here participate in binding of LCAT to HDL particles and are part of a complex interaction between LCAT, the lipid substrates and activator protein(s) on the surface ofthe lipoprotein particle. Under normal conditions, LCAT is presumably continuously transferred from mature, spherical HDL to newly secreted nascent HDL particles with only a small portion of the LCAT enzyme associated with apo B containing lipoprotein particles (45) . However, the equilibrium state and distribution of the LCAT enzyme in plasma may be shifted towards LDL and VLDL in the Swedish patients and in our proband. Biochemical data strongly suggest that the only enzymically active domain of LCAT consists of a serine residue at position 181 (46) (47) (48) , whereas the two free cysteines at positions 31 and 184 appear not to be an integral part of the catalytic domain, as recently demonstrated by site-directed mutagenesis of the LCAT gene (49) . The normal CER in the Swedish subjects and in our patient indicates that the catalytic site of the enzyme is intact, pointing to a defective interaction ofLCAT with HDL particles in these patients.
Several molecular defects in the LCAT gene have now been identified in classic LCAT deficiency (Fig. 4) (Table III) . The class I defect is characterized by absent or extremely low levels ofCER and LCAT activity, indicating a total functional loss ofLCAT activity. This could be the consequence ofmolecular defects in the LCAT gene resulting in (a) a null allele, (b) a synthesis defect, (c) an enzyme with impaired binding to both HDL and VLDL-LDL, or (d) a functionally inactive enzyme. The presence oftwo class I alleles resultstherefore in the clinical features of classic LCAT deficiency. Class II defects are characterized by a partial loss in LCAT function, namely in a-LCAT activity, and a nearly normal CER, but a virtual absence of LCAT activity using the proteoliposome assay. In this case, the catalytic domain is presumably intact as indicated by the capability of the enzyme to generate normal levels of plasma cholesteryl esters, but the interaction with HDL particles is defective. Patients with two class II alleles, who are either homozygous for one defect or compound heterozygous for two class II defects, as described here, develop corneal opacities, but no atherosclerosis or renal disease. LCAT deficient patients who are compound heterozygotes with one class I allele and one class II allele would be anticipated to have intermediate biochemical abnormalities as well as variable clinical features. A potential third variant of LCAT defects, which could exclusively affect the interaction of the LCAT enzyme with apo B-containing lipoprotein particles is conceiv- 
